Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. The company focuses on genetic diseases of the central nervous system and liver. Its pipeline products include CMP-CPS-001 and CMP-SYNGAP. The company operates as a single operating segment, R&D, which engages in the development of a new class of RNA-based therapeutics to treat a broad range of genetic diseases.
Last trade$4.03
Day change+$0.17 (+4.40%)
Day range$3.71 – $4.10
Volume139,449
Market cap$242M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$242.23M
Price / earnings
—
Price / book
2.26×
Price / sales
45.53×
EV / sales
22.13×
EV / EBITDA
-2.29×
Profitability
Earnings per share
-$1.93
Return on assets
-90.37%
Return on equity
-113.08%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
6.42×
Quick ratio
6.42×
Cash ratio
6.27×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$26.41M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CAMP, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$1.9M
$1.78M
$1.29M
$348K
$795K
$1.5M
$858K
$652K
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$1.9M
$1.78M
$1.29M
$348K
$795K
$1.5M
$858K
$652K
Selling, general and administrative
$4.49M
$4.34M
$4.21M
$4.77M
$4.6M
$4.18M
$3.81M
$4.69M
Research and development
$11.43M
$10.82M
$10.16M
$8.36M
$9.85M
$10.34M
$10.15M
$10M
Total operating expenses
$15.93M
$15.16M
$14.37M
$13.12M
$14.45M
$14.53M
$13.96M
$14.69M
Operating income
-$14.03M
-$13.38M
-$13.07M
-$12.78M
-$13.65M
-$13.03M
-$13.1M
-$14.03M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$28.96M
-$33.53M
-$18.33M
-$40.28M
-$15.1M
-$12.59M
-$12.43M
-$13.28M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$28.96M
-$33.53M
-$18.33M
-$40.28M
-$15.1M
-$12.59M
-$12.43M
-$13.28M
Net income attributable to common shareholders
-$28.96M
-$33.53M
-$18.33M
-$40.28M
-$15.1M
-$12.59M
-$12.43M
-$13.28M
EBITDA
-$13.51M
-$12.87M
-$12.55M
-$12.4M
-$13.24M
-$12.6M
-$12.68M
-$13.62M
Basic earnings per share
-$0.37
-$0.58
-$0.32
-$0.75
-$0.55
-$0.62
-$0.62
-$0.77
Diluted earnings per share
-$0.37
-$0.58
-$0.32
-$0.75
-$0.55
-$0.62
-$0.62
-$0.77
Recent news
Company coverage with links to the original publishers.
CAMP4 Therapeutics reported a Q3 loss of $0.17 per share, beating EPS estimates but missing revenue expectations at $1.9 million. The stock has underperformed the market by 39% year-to-date. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, and is expected to post continued losses in upcoming quarters.
CAMP4 Therapeutics announced it received Clinical Trial Application (CTA) approval from European Union regulatory authorities to initiate its Phase 1/2 ASCEND clinical trial of CMP-002 for SYNGAP1-related disorder. This approval follows clearances from the United Kingdom, Australia, and Argentina, expanding the global footprint of the trial. The company anticipates dosing the first patient in Q4 2026. CMP-002 is designed to increase SYNGAP1 gene expression and restore protein levels in patients with this rare genetic disorder that currently has no approved disease-modifying treatments.
CAMP4 Therapeutics announced its participation in a panel discussion titled 'RNA Medicines: Transcriptome Engineering' at Chardan's 10th Annual Healthcare Conference on October 20, 2026. The panel will be held in New York and webcast live, with a 30-day replay available on CAMP4's investor relations website.
CAMP4 Therapeutics granted non-qualified stock options to purchase 39,000 shares to three newly hired employees as inducement for employment. The options have a 10-year term, an exercise price of $3.96 per share, and will vest over four years with 25% vesting after one year followed by monthly installments.
CAMP4 Therapeutics granted 8,000 non-qualified stock options to a newly hired employee on February 16, 2026, with an exercise price of $3.85 per share. The options vest over four years with a ten-year term, reflecting the company's continued hiring and growth in its RNA-targeting therapeutics pipeline.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.